Savara Inc (NASDAQ:SVRA) insider Jaakko Taneli Jouhikainen sold 25,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $12.85, for a total transaction of $321,250.00. Following the sale, the insider now directly owns 219,216 shares in the company, valued at $2,816,925.60. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Savara Inc (NASDAQ:SVRA) opened at $11.93 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.15 and a current ratio of 9.15. Savara Inc has a 52-week low of $4.60 and a 52-week high of $17.19. The company has a market cap of $363.87, a PE ratio of -3.55 and a beta of -0.26.
SVRA has been the topic of several analyst reports. Canaccord Genuity boosted their price target on shares of Savara from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 30th. Roth Capital cut their price target on shares of Savara from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, October 31st. Zacks Investment Research cut shares of Savara from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd. ValuEngine cut shares of Savara from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Savara in a research report on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. Savara presently has an average rating of “Buy” and a consensus target price of $23.58.
ILLEGAL ACTIVITY WARNING: “Jaakko Taneli Jouhikainen Sells 25,000 Shares of Savara Inc (SVRA) Stock” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/02/21/jaakko-taneli-jouhikainen-sells-25000-shares-of-savara-inc-svra-stock.html.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.